AU2001232337A1 - Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance - Google Patents

Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance

Info

Publication number
AU2001232337A1
AU2001232337A1 AU2001232337A AU3233701A AU2001232337A1 AU 2001232337 A1 AU2001232337 A1 AU 2001232337A1 AU 2001232337 A AU2001232337 A AU 2001232337A AU 3233701 A AU3233701 A AU 3233701A AU 2001232337 A1 AU2001232337 A1 AU 2001232337A1
Authority
AU
Australia
Prior art keywords
reagent
pharmaceutical composition
active ingredient
pharmaceutically active
labeling substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232337A
Inventor
Noriaki Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanagawa Academy of Science and Technology
Mitsubishi Chemical Corp
Original Assignee
Kanagawa Academy of Science and Technology
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Academy of Science and Technology, Mitsubishi Chemical Corp filed Critical Kanagawa Academy of Science and Technology
Publication of AU2001232337A1 publication Critical patent/AU2001232337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001232337A 2000-02-18 2001-02-19 Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance Abandoned AU2001232337A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-41303 2000-02-18
JP2000041303 2000-02-18
PCT/JP2001/001167 WO2001060411A1 (en) 2000-02-18 2001-02-19 Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance

Publications (1)

Publication Number Publication Date
AU2001232337A1 true AU2001232337A1 (en) 2001-08-27

Family

ID=18564561

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232337A Abandoned AU2001232337A1 (en) 2000-02-18 2001-02-19 Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance

Country Status (3)

Country Link
US (1) US20030050227A1 (en)
AU (1) AU2001232337A1 (en)
WO (1) WO2001060411A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
WO2003031464A2 (en) 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2322229B1 (en) 2001-10-10 2016-12-21 Novo Nordisk A/S Remodeling and glycoconjugation of Factor IX
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
KR20060003862A (en) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. Branched water-soluble polymers and their eonjugates
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05011832A (en) 2003-05-09 2006-02-17 Neose Technologies Inc Compositions and methods for the preparation of human growth hormone glycosylation mutants.
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
WO2005039291A2 (en) * 2003-10-22 2005-05-06 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
EP1694347B1 (en) 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
ATE455861T1 (en) 2004-05-04 2010-02-15 Novo Nordisk Healthcare Ag O-LINKED GLYCOFORMS OF FACTOR VII AND METHOD FOR THE PRODUCTION THEREOF
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
ES2572779T3 (en) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodeling and glucopegilation of Fibroblast Growth Factor (FGF)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP2008538569A (en) * 2005-04-20 2008-10-30 フレッド ハッチンソン キャンサー リサーチ センター Methods, compositions, and articles of manufacture for enhancing the viability of cells, tissues, organs, and organisms
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
ES2406267T3 (en) 2007-04-03 2013-06-06 Biogenerix Ag Treatment methods using glycopegylated G-CSF
JP5876649B2 (en) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ Improved process for producing nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules

Also Published As

Publication number Publication date
WO2001060411A1 (en) 2001-08-23
US20030050227A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
AU2001232337A1 (en) Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
IL145983A0 (en) Pharmaceutical composition for dermal use, comprising a corticosteroid and a vitamin d or an analogue thereof
AU2879100A (en) Formulation and system for intra-oral delivery of pharmaceutical agents
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
AU7601998A (en) Composition and methods for transdermal delivery of acid labile drugs
HUP0301688A3 (en) Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
HUP0101512A3 (en) Adhesive microsphere drug delivery composition, process for its preparation and device containing it
AU2001226029A1 (en) Pharmaceutical formulation and method for pulmonary and oral delivery
EE05506B1 (en) Drug delivery device, especially for administration of progestins and strogens
AU2002236647A1 (en) Method and device for administering medication and/or placebo
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2001234114A1 (en) Drugs containing combined active ingredients
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
WO2001041742A3 (en) Antiviral medication
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
IL123927A (en) Propanolamine derivatives processes for their preparation and pharmaceutical composition comprising them
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
HUP0204202A3 (en) Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
AU5072000A (en) Pharmaceutical composition for nasally administering water-soluble active substances
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2570001A (en) Pharmaceutical composition and method for its manufacture